Alnylam Pharmaceuticals Investment Purchases increased by 10.9% to $261.63M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 34.9%, from $401.64M to $261.63M. Over 4 years (FY 2021 to FY 2025), Investment Purchases shows a downward trend with a -5.8% CAGR.
An increase indicates a surplus of cash being deployed into financial markets rather than core operations; a decrease may suggest a need for liquidity.
The total cash outflow for the acquisition of debt and equity securities, including marketable securities and other fina...
Large-cap technology firms often show high outflows here as they manage massive cash reserves across global portfolios.
purchases_of_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $168.86M | $458.33M | $682.97M | $634.71M | $461.57M | $157.31M | $723.38M | $435.75M | $377.14M | $421.46M | $589.16M | $420.12M | $297.71M | $430.38M | $486.71M | $401.64M | $459.56M | $207.97M | $235.91M | $261.63M |
| QoQ Change | — | +171.4% | +49.0% | -7.1% | -27.3% | -65.9% | +359.8% | -39.8% | -13.4% | +11.8% | +39.8% | -28.7% | -29.1% | +44.6% | +13.1% | -17.5% | +14.4% | -54.7% | +13.4% | +10.9% |
| YoY Change | — | — | — | — | +173.3% | -65.7% | +5.9% | -31.3% | -18.3% | +167.9% | -18.6% | -3.6% | -21.1% | +2.1% | -17.4% | -4.4% | +54.4% | -51.7% | -51.5% | -34.9% |